Arcutis Biotherapeutics, Inc. research snapshot
ARQT AI stock analysis reads Arcutis Biotherapeutics as a commercial-stage dermatology company that has successfully transitioned from a development-stage biotech to a revenue-generating business driven by ZORYVE (roflumilast) across multiple indications including plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. At the July 12, 2026 data cutoff, ARQT traded near $27.74 with a verified market capitalization near $3.47 billion. The company reported FY2025 revenue near $376 million and is approaching operating breakeven. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$27.74
Market cap
$3.47 billion
AI score
65 / 100
Rating
Commercial-stage dermatology biotech with ZORYVE momentum, approaching profitability
Trend status
Up more than 100% from 52-week low on ZORYVE label expansion and revenue growth
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Arcutis sells patented topical PDE4 inhibitor therapies (ZORYVE) for inflammatory skin diseases through a specialty dermatology sales force targeting physicians and payers. | Medium |
| Moat | Moat comes from ZORYVE patents, FDA-approved label exclusivity, formulation know-how, and development of a branded dermatology franchise. Rivals can develop competing topicals, and branded market access depends on formulary placement. | Low-medium |
| Management | CEO Frank Watanabe has steered Arcutis from development to commercial stage, secured FDA approvals across multiple indications, managed the cash position through the transition, and grown revenue to a $376M run rate. Capital allocation and profitability timeline are key open questions. | Medium |
| Financial trend | Revenue has grown from zero to $376M (FY2025) on ZORYVE sales across psoriasis, seborrheic dermatitis, and atopic dermatitis. Gross margins are stable near 90%+, operating expenses remain high as SG&A and R&D scale. Net loss narrowed to -$16M in FY2025. | Medium-high |
| Valuation | At $27.74 and $3.47B market cap, ARQT trades at roughly 9.2x FY2025 revenue. The stock is priced for continued label expansion and profitability by FY2027. Premium to large biopharma requires sustained 30%+ revenue growth. | Medium |
| Technical trend | ARQT is up over 100% from the 52-week low of $13.70, trading near $27.74 with resistance around $31.77 (52-week high) and support near $22. Momentum is positive but extended. | Medium |
| Risk level | Elevated. Regulatory dependence (FDA label expansion), competitive pressure in topical dermatology, payer access and formulary placement, potential dilution, single-product franchise risk, and volatile biotech sentiment. | Medium |
| AI confidence | Medium. Revenue, share count, and market cap data are well-sourced, but competitive positioning, label trajectory, and long-term margin structure depend on execution factors that require ongoing monitoring. | Medium |
| Investment certainty | Medium-low. Arcutis is a real revenue-generating business with growing adoption, but the stock price already reflects optimism about continued ZORYVE expansion. The gap between data confidence and investment certainty is wider than for established profitable companies. | Low-medium |
ARQT AI stock forecast
Three ARQT scenarios explore how ZORYVE label expansion, competitive dynamics, and execution toward profitability could affect the stock over the next 12-24 months. These are not predictions, only probability-weighted ranges.
$36 - $45
FDA approves additional indications (hand eczema, vitiligo, alopecia areata) expanding the addressable market significantly. ZORYVE achieves tier 2/3 payer coverage in atopic dermatitis. Arcutis reaches GAAP profitability in FY2026 and revenue exceeds $600M, justifying a higher multiple on a sustainable commercial biotech platform.
$26 - $36
ZORYVE continues to gain share in approved indications at a moderate pace. Payer coverage gradually improves. Revenue grows 25-35% year-over-year. Arcutis narrows operating losses and approaches breakeven by FY2027. Stock trades in line with commercial-stage biotech peers at 7-10x forward revenue.
$14 - $22
ZORYVE faces unexpected competitive launches or payer restrictions that slow adoption. An FDA setback delays or narrows a key label expansion. Arcutis needs additional financing, diluting shareholders. Operating losses persist longer than expected, compressing the valuation multiple toward pre-profitability biotech levels.
ARQT AI technical analysis
Technical levels as of the July 12, 2026 data cutoff. ARQT shows a strong uptrend from the 52-week low but faces resistance near the highs. Levels are based on recent price action and may shift with new data.
| Level | Value | Why it matters |
|---|---|---|
| Resistance (52-week high) | $31.77 | Previous cycle peak. A clean breakout above would signal continuation of the uptrend and open the path toward analyst targets near $34-$36. |
| Immediate resistance | $28.70 - $29 | Recent price rejection zone. Short-term sellers have emerged near this level following the Q1 2026 earnings report. |
| Support (20-day MA) | $24.50 | Near-term trend level. Holding above this moving average keeps the short-term uptrend intact. |
| Key support (50-day MA) | $22.00 | Important intermediate support. A break below this level with volume would suggest momentum is fading. |
| Major support | $17.50 - $18.00 | Prior consolidation zone from late 2025. This level would become relevant only in a significant trend reversal. |
| Volume trend | Above average | Recent trading volume has been above the 50-day average, confirming institutional interest in the ZORYVE commercial story. |
| RSI (14-day) | Neutral-bullish | RSI near 55-60, not yet overbought, suggesting room for further upside if buying interest continues. |
| Invalidation level | Below $13.70 | A break below the 52-week low would invalidate the current uptrend and suggest a fundamental reassessment of the ZORYVE opportunity. |
ARQT AI trading strategy
These frameworks are for informational and educational use. They are not personalized investment advice. ARQT is a commercial-stage biotech with binary event risk around FDA label decisions, payer coverage changes, and competitive dynamics. Position sizing should account for above-average volatility.
Look for dips toward the 20-day or 50-day moving average as potential entry zones in an established uptrend. Enter when price holds above support and RSI resets from overbought levels. Set initial targets near the 52-week high ($31.77) then analyst targets ($34-$36).
Stop below the 50-day MA (~$22). If the stock breaks below the 200-day MA, the trend has likely turned. Position size at 2-3% of portfolio given biotech volatility.
Biotech stocks often overshoot on FDA news. On sharp pullbacks of 15-20% without a fundamental change, consider mean-reversion entries. Key catalyst zones are FDA decision dates, earnings reports, and clinical trial data releases.
Define the catalyst date and exit if the thesis does not materialize within the expected timeframe. Biotech gaps can be large; use defined-risk option structures if available.
ARQT is a single-product franchise with regulatory and commercial binary risk. No single position should expose more than 5% of portfolio. Consider reducing exposure ahead of FDA decision dates or earnings reports with wide expected moves.
Set a maximum loss threshold before entering. If the stock gaps down more than 20% on negative news, reassess the fundamental thesis before adding to the position. Do not average down into a broken thesis.
Investment research summary
Arcutis develops and commercializes topical PDE4 inhibitors for inflammatory skin diseases. Its lead product ZORYVE (roflumilast) is approved for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. The company targets the large dermatology market where topical treatments are first-line therapy and there is demand for safer steroid-free alternatives.
ZORYVE patent protection, formulation IP, FDA exclusivity, and a growing body of clinical data provide some competitive insulation. However, dermatology is crowded with established branded products from Novartis, Leo Pharma, Bausch Health, and Pfizer. Switching costs are low for physicians who can prescribe competing topicals. The moat is narrow and depends on continued innovation and label expansion.
The thesis fails if: (1) ZORYVE label expansion slows or hits FDA roadblocks, (2) payer coverage and reimbursement are narrower than expected, limiting the addressable market, (3) a competitor launches a superior or cheaper topical that captures share, (4) the company cannot achieve profitability without dilutive financing, (5) the single-product franchise structure leaves no buffer if ZORYVE disappoints.
CEO Todd Franklin Watanabe has led Arcutis from preclinical development through multiple FDA approvals and commercial launch. The team has executed label expansions across three indications. Key questions include whether management can scale the commercial organization to compete with much larger dermatology sales forces and how they will allocate capital between R&D pipeline investment and profitability.
Dermatology is a large and growing market driven by an aging population, increasing skin disease awareness, and demand for steroid-sparing treatments. The shift toward targeted topical therapies (PDE4, JAK, AhR agonists) creates opportunity for newer agents. However, payer scrutiny of branded specialty topicals is increasing, and biosimilar/dermatology generic competition looms for older products.
At $27.74 and $3.47B market cap, ARQT trades at ~9.2x FY2025 revenue of $376M. Analyst price targets range from $33 to $36, implying 20-30% upside. The current valuation assumes continued revenue growth and a path to profitability. There is limited margin of safety if growth decelerates or label expansion disappoints, as the stock would re-rate to a lower multiple.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $27.74 | TradingView | 2026-07-12 |
| Market capitalization | $3.47 billion | TradingView, Google Finance | 2026-07-12 |
| Shares outstanding | 125.08 million | Google Finance | 2026-07-12 |
| Revenue (FY2025) | $376.07 million | TradingView | 2026-07-12 |
| Net income (FY2025) | -$16.14 million | TradingView | 2026-07-12 |
| EPS (TTM) | -$0.02 | TradingView | 2026-07-12 |
| Q1 2026 revenue | $105.40 million | Google Finance | 2026-07-12 |
| 52-week high | $31.77 | Google Finance | 2026-07-12 |
| 52-week low | $13.70 | Google Finance | 2026-07-12 |
| Employees | 354 | TradingView | 2026-07-12 |
| Analyst consensus | Buy (7/7 analysts), average target $34.86 | Google Finance | 2026-07-12 |
This ARQT AI stock analysis page is an informational tool only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. All analysis is based on publicly available data as of the data cutoff date and uses scenario frameworks that may prove incorrect. Past performance is not indicative of future results. Investing in biotech stocks carries risks including potential total loss of capital. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
